MX2023001466A - Enlazadores de base peptidica. - Google Patents

Enlazadores de base peptidica.

Info

Publication number
MX2023001466A
MX2023001466A MX2023001466A MX2023001466A MX2023001466A MX 2023001466 A MX2023001466 A MX 2023001466A MX 2023001466 A MX2023001466 A MX 2023001466A MX 2023001466 A MX2023001466 A MX 2023001466A MX 2023001466 A MX2023001466 A MX 2023001466A
Authority
MX
Mexico
Prior art keywords
peptide
drug conjugates
linkers
based linkers
relates
Prior art date
Application number
MX2023001466A
Other languages
English (en)
Inventor
Gemma Mudd
Paul Beswick
Kevin Mcdonnell
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MX2023001466A publication Critical patent/MX2023001466A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a novedosos enlazadores que comprenden dos o tres aminoácidos básicos, ácidos o hidrofóbicos, naturales o no naturales; la invención también se refiere a conjugados de fármacos que comprenden dichos enlazadores, a composiciones farmacéuticas que comprenden dichos conjugados de fármacos y al uso de dichos conjugados de fármacos para prevenir, suprimir o tratar el cáncer.
MX2023001466A 2020-08-03 2021-08-03 Enlazadores de base peptidica. MX2023001466A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063060344P 2020-08-03 2020-08-03
PCT/GB2021/052001 WO2022029420A1 (en) 2020-08-03 2021-08-03 Peptide-based linkers

Publications (1)

Publication Number Publication Date
MX2023001466A true MX2023001466A (es) 2023-03-03

Family

ID=77358296

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001466A MX2023001466A (es) 2020-08-03 2021-08-03 Enlazadores de base peptidica.

Country Status (11)

Country Link
US (1) US20220031858A1 (es)
EP (1) EP4188938A1 (es)
JP (1) JP2023536192A (es)
KR (1) KR20230074119A (es)
CN (1) CN116348476A (es)
AU (1) AU2021322934A1 (es)
BR (1) BR112023001428A2 (es)
CA (1) CA3189761A1 (es)
IL (1) IL300248A (es)
MX (1) MX2023001466A (es)
WO (1) WO2022029420A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3559018A1 (en) 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5159798A (en) 1996-11-05 1998-05-29 Bristol-Myers Squibb Company Branched peptide linkers
EP2257624B9 (en) 2008-02-05 2012-08-01 Medical Research Council Methods and compositions
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
CA3220466A1 (en) 2014-10-29 2016-05-06 Bicyclerd Limited Bicyclic peptide ligands specific for mt1-mmp
US10011657B2 (en) * 2014-10-31 2018-07-03 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
JP2018502067A (ja) 2014-12-04 2018-01-25 セルジーン コーポレイション 生体分子複合体
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
JP2020529427A (ja) 2017-08-04 2020-10-08 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
MX2020004691A (es) * 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
TWI825046B (zh) * 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基

Also Published As

Publication number Publication date
US20220031858A1 (en) 2022-02-03
BR112023001428A2 (pt) 2023-02-23
CA3189761A1 (en) 2022-02-10
CN116348476A (zh) 2023-06-27
KR20230074119A (ko) 2023-05-26
EP4188938A1 (en) 2023-06-07
WO2022029420A1 (en) 2022-02-10
IL300248A (en) 2023-03-01
JP2023536192A (ja) 2023-08-23
AU2021322934A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
PH12017501580A1 (en) Antibody drug conjugates (adc) that bind to flt3 proteins
IN2015DN04147A (es)
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
WO2020236825A3 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
EA201691059A1 (ru) Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство
UA97095C2 (ru) Противораковая вакцина, которая содержит опухолевоассоциированный пептид, который связывается с молекулами лейкоцитарного антигена человека (hla) класса i или ii, и ее применение в производстве лекарственного средства
EA201300411A1 (ru) Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
PH12015500392A1 (en) Antibody drug conjugates (adc) that bind to 158p1d7 proteins
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
MX2018014631A (es) Formulacion de neurotoxina.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
NZ704285A (en) Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery
MX2023002330A (es) Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos.
MX2023001466A (es) Enlazadores de base peptidica.
BRPI1006076B8 (pt) composições farmacêuticas
PH12020551618A1 (en) Erenumab compositions and uses thereof
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.